A paper blotter and skin provide different evaluation conditions. For perfume development, compare the same identified sample on both rather than assuming one predicts the other. Record the dose, surface, environment and elapsed time before attributing a difference to the formula or the participant.
How Blotters and Skin Interact with Fragrance Differently
The Blotter Test: A Controlled Reference Surface
Use one specified blotter model and lot for a comparison, with unused paper as an odor control. Paper is a test surface, not a guarantee of chemically neutral or linear development. A published experimental study compared an eight-molecule ethanol mixture on glass, a model membrane, a test strip and skin using headspace measurements. Its method does not establish that paper predicts the sensory wear of every finished perfume.
Skin Evaluation: A Separate Test Track
A volunteer evaporation study investigated differences between people and associations with measured skin and molecular properties. This supports documenting participant variability, not diagnosing a particular odor change from pH, diet or hormones. Instrumental evaporation and a panel’s sensory description are different outcomes.
Variables to Control Before Interpreting Differences
Skin Properties and Preparation
Specify the application site and preparation in the approved protocol. Record relevant preparation deviations and permitted personal-care products. Do not infer that oily skin always extends wear or that a higher pH makes a fragrance sweeter; neither is a product-specific acceptance rule.
Body Temperature
Record the room conditions and, if the method requires it, skin temperature using the agreed method. Keep the application site consistent. A temperature difference should prompt a controlled comparison rather than an automatic prediction of stronger projection or shorter wear.
Moisturizers and Other Applied Products
A lotion or other applied product introduces another test condition. Keep it absent or standardized in the comparison; if layering is part of the intended use, evaluate it as a separately identified condition rather than recommending it as a universal fix.
Participant Differences and Study Limits
Use coded participant records and collect only information justified by the approved study. Report the population and exclusions without attributing results to medication, diet or hormones that the study did not measure. Any skin evaluation needs a qualified team’s approved protocol, informed participation, suitability review and stop/report procedure. Use only the finished-use sample approved for that protocol, never an unspecified fragrance concentrate.
Comparing Blotter vs. Skin
| Comparison item | Blotter track | Skin track |
|---|---|---|
| Surface | Record paper brand/model, lot and dimensions | Record approved site and preparation |
| Application | Record sample code, concentration, dose and application method | Use the same sample identity; define and record the approved dose |
| Conditions | Record temperature, humidity, airflow and storage between readings | Record the same environmental factors and permitted activities |
| Control | Unused blotter and an identified reference sample | Protocol-approved control/reference and coded participant |
| Readout | Describe odor and intensity at preselected times | Describe odor, intensity and defined projection endpoint at those times |
Draft Dual-Track Evaluation SOP for a Buyer’s Project
The paper-track design below supplies a finite comparison example. Its numerical choices are proposed by the author, not a validated factory SOP, a standard’s required settings or completed research. Actual sample identities and approvals must be entered before use. The skin track remains gated to a separate approved, product-specific protocol. Use the sample feedback guide and longevity and projection evaluation guide to keep observations and approval decisions separate.
Proposed paper comparison: EX-COMPARE-01, revision 1
Status: NOT RUN, NOT APPROVED. Scope: descriptive comparison of two identified finished-use samples A and B with an agreed finished-use reference R. The project’s qualified evaluator and safety reviewer must approve the actual samples, handling and sensory exposure before anyone participates. Do not use unspecified concentrates. Paper application conditions are not skin-use directions or safe-exposure limits.
| Parameter | Proposed setting and record |
|---|---|
| Paper and lot | Use unprinted HGV 10140 BC square-edge blotters, 10 × 140 mm, from one recorded lot. The manufacturer lists this model and size. Do not treat the paper as chemically inert. A different model or lot starts a separately identified comparison. |
| Samples, reference and baseline | Register A, B and R with formula revision, concentration as supplied, batch/lot, preparation date, storage and opening time. R is a mutually agreed retained comparison sample, not an invented approved standard. Include one untreated blotter per set; check room/background odor and each unused strip before dosing. Record these baselines. An interfering odor or contaminated blank puts the set on HOLD. |
| Paper dose and placement | 10.0 µL per treated strip, delivered once at a point 10 mm from the square end, centered across its width. Use a calibrated positive-displacement pipette with a suitable 10 µL range and a new compatible tip for each sample. Record pipette/tip IDs and verification of actual-fluid delivery to the example’s ± 0.5 µL tolerance. Do not replace the measured volume with an unmeasured spray or dip. Overflow, incomplete transfer or a different dose is a deviation, not a valid replicate. |
| Room and storage | 23 ± 2 °C and 50 ± 10% RH; record actuals at application and each reading. Keep one documented room, ventilation setting and rack layout, away from direct sun and directed drafts; do not turn off required safety ventilation. Keep strips upright, treated ends exposed and at least 10 cm apart, without touching or enclosing them together. Record any moved rack or ventilation change. |
| Evaluators and replication | Two consenting adult evaluators, coded E01/E02, briefed on the same descriptors and scale; three sessions 24 ± 2 hours apart. Each evaluator receives a fresh separate set of A, B, R and untreated paper per session: 24 strips total. This small design supports a project discussion, not consumer-preference, population or safety claims. |
| Coding and order | A coordinator keeps the identity key and gives each treated strip a new random three-digit code. Randomly assign the six A/B/R orders (ABR, ARB, BAR, BRA, RAB, RBA), one to each evaluator-session pair, and save that assignment before dosing. Keep its order across that set’s timepoints. Assess the blank first. Reveal identities only after the session records are locked. |
| Clocks and readings | Stagger treatment of A/B/R in the assigned order by 90 seconds and start an individual clock when each transfer finishes. Read each treated strip at 5 ± 0.5, 30 ± 1 and 120 ± 2 minutes from its own start; record actual elapsed times. Use the same approved presentation: treated end 3 cm from the nose, one brief assessment up to 2 seconds, with at least 60 seconds before the next strip. These are draft comparison settings requiring exposure approval, not safety thresholds; stop for discomfort and follow the approved reporting procedure. |
| Recording and outcome | Before coding, agree a descriptor list and intensity anchors: 0 = not detected, 1 = weak, 2 = moderate, 3 = strong, 4 = very strong. Keep individual coded scores and free-text descriptors at every timepoint, including the untreated blank. No projection or wear-duration endpoint is claimed. Retain evaluator identity only as a code in the comparison sheet. |
Run and review: confirm approvals and register materials → record baselines → lock the code/order sheet → prepare separate strips and start their clocks → record each scheduled assessment independently → lock records before decoding → compare A/B with R at matching times and within the same evaluator. There are 54 treated-strip assessments (3 samples × 2 evaluators × 3 sessions × 3 times), plus the blank checks. Report the individual scores, per-evaluator range across sessions and recurring or conflicting descriptors; do not call this design statistically powered or average away disagreement. Missing times, changed conditions, contaminated controls or dosing errors stay visible as deviations. The reviewer either accepts the record for descriptive discussion, requests a documented new comparison or places it on HOLD. A complete record is not a product PASS.
Skin-track gate and matched comparison record
Skin status: NOT AUTHORIZED BY THIS EXAMPLE. Before this track can become executable, the qualified team must issue a protocol/version covering the specific finished samples and reference, participant suitability and number, informed participation, application site and area, product-specific dose and delivery, preparation and permitted products/activities, control condition, environmental limits, observation times, assessor presentation, repeats/washout, stop/report procedure and responsible signatories. Copy those approved parameters into the project record; do not copy the paper dose, paper presentation distance or literature dose onto skin. No skin application is instructed here.
If a skin protocol is approved, use the same versioned A/B/R identities and a separate coded record for each participant, surface and elapsed time; record the pre-application baseline and actual approved conditions. Compare tracks only at the times and conditions that genuinely match, and show any different dose or presentation explicitly. Paper-versus-skin observations alone do not identify a causal mechanism, prove safety or predict all customers. The existing volunteer evaporation paper used instrumental headspace analysis of a defined mixture; it does not validate this sensory worksheet or supply a universal skin dose.
Before use, the coordinator signs the identity/code/order and timing plan, the qualified evaluator signs the descriptors and comparison scope, and the safety reviewer signs the permitted materials and exposure protocol. Afterward, the operator signs actual observations/deviations and the responsible reviewer signs the bounded conclusion. The blank record below remains a place for real entries; no results or approvals are supplied here. Eppendorf’s liquid-handling guidance supports selecting positive-displacement equipment for volatile or viscous liquids; it does not establish the example dose or prove delivery performance with the actual fragrance.
FAQ
Why does the same perfume smell different on my friend?
A reported difference may reflect the participant, application, environment, sample or evaluation conditions. Repeat a coded comparison before assigning a cause. One person’s result does not establish how all customers will experience the perfume.
Can I make a fragrance last longer on my skin?
For development, evaluate the approved finished formula under its intended use rather than adding unvalidated oils, lotions or extra doses. If a different application routine is part of the brief, record it as a separate condition and compare the results.
Does the time of year affect how a perfume smells on skin?
Season names do not define a test environment. Record actual temperature, humidity, airflow and activity, then compare results under the conditions relevant to the brief. Do not infer a fixed seasonal effect from a single observation.
Is it true that perfumes smell different on blotter paper over time?
Record each blotter reading at a stated elapsed time, with the same paper and handling method. Compare those observations with the skin track at matched times; do not assume that late paper notes must be absent on skin.
Blank Dual-Track Evaluation Record
| Field | Project entry |
|---|---|
| Protocol version, approvers and date | [Complete before use] |
| Sample/batch, formula version and concentration | [Record] |
| Paper model/lot; blank and reference codes | [Record] |
| Dose and application method for each track | [Specify and verify] |
| Participant criteria, number, coded IDs and skin-use approval | [Approve; keep personal records controlled] |
| Temperature, humidity, airflow and permitted activities | [Specify targets; record actuals] |
| Reading times, blind coding/order and repeat plan | [Set before testing] |
| Descriptors, intensity scale and projection method | [Define anchors, distance and evaluator role] |
| Results by track/time, deviations and stop reports | [Complete after testing] |
| Pass/revise criteria, decision and reviewer | [Set criteria in advance; record decision later] |
Request a Quote to discuss a fragrance development brief, the available samples and an appropriate evaluation scope.